An integrated systems biology approach to investigate immunopotentiation induced by Respiratory Syncytial Virus vaccines


Funding period: 2014-2019
Lead: Sean Li
Total GRDI funding: $1,192,000

Respiratory Syncytial Virus is a common and highly contagious virus that infects the respiratory tract of infants, young children and seniors, and is the most common cause of bronchitis. At this time, there is no vaccine available for the prevention of diseases induced by this virus. This is largely due to a lack of understanding of the virus's disease processes and relevant evaluation tools for vaccine assessments. In this project, Health Canada's researchers are using a genomics approach to better understand the vaccine-induced toxicity and establish regulatory tools to ultimately assess the safety of this vaccine.

Contact us

For additional information, please contact:
Genomics R&D Initiative